{"text":"It shall be unlawful for any drug manufacturer or licensee thereof, excluding a point of sale retail seller, to sell or supply for sale or impose minimum resale requirements for a patented prescription drug that results in the prescription drug being sold in the District for an excessive price.","historical":"Legislative History of Laws\n\nFor Law 16-37, see notes following ยง 28-4551.\n\nDC CODE ยง 28-4553\n\nCurrent through December 11, 2012","credits":"(Dec. 10, 2005, D.C. Law 16-37, ยง 2, 52 DCR 9061.)\n\nGENERAL NOTES\n\nThis chapter has been held unconstitutional in the case of Pharmaceutical Research and Mfrs. of America v. District of Columbia, 2005, 406 F.Supp.2d 56, 78 U.S.P.Q.2d 1822, affirmed 496 F.3d 1362, 83 U.S.P.Q.2d 1639, rehearing and rehearing en banc denied 505 F.3d 1343, 85 U.S.P.Q.2d 1144.","sections":[],"division":{"identifier":"V","text":"Local Business Affairs"},"title":{"identifier":"28","text":"Commercial Instruments and Transactions. (Refs & Annos)"},"subtitle":{"prefix":"II","text":" Other Commercial Transactions."},"chapter":{"identifier":"45B","text":"Excessive Pricing."},"heading":{"title":"28","chaptersection":"4553","identifier":"28-4553","catch_text":"Excessive pricing in sales of prescription drugs, a violation of law."}}